Product Information

CAS No.	845614-11-1
Product Name	Bitopertin

Biological Targets

SLC6A9

Associated Conditions

obsessive-compulsive disorder·schizophrenia·Diamond-Blackfan anemia·Beta-thalassemia·erythropoietic protoporphyria

* The information provided here is compiled from public sources and is for reference only.

Studies related to this compound and its mechanism of action

Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.

Journal of medicinal chemistry • Vol. 61, Issue 17 • 2018

PMID: 30080045 DOI: 10.1021/acs.jmedchem.8b00300

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

Biological psychiatry • Vol. 82, Issue 1 • 2017

PMID: 28117049 DOI: 10.1016/j.biopsych.2016.11.014

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.

The lancet. Psychiatry • Vol. 3, Issue 12 • 2016

PMID: 27816567 DOI: 10.1016/S2215-0366(16)30344-3

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology • Vol. 24, Issue 7 • 2014

PMID: 24735806 DOI: 10.1016/j.euroneuro.2014.03.007

Bitopertin

CAS No.	845614-11-1
MDL No.	MFCD18251496
MF	C₂₁H₂₀F₇N₃O₄S
MW	543.50
InChI Key	YUUGYIUSCYNSQR-LBPRGKRZSA-N

CUSTOM SYNTHESIS PRECLINICAL SUPPORT

Pricing & Availability

Pack Size	Purity	Price	Availability	Action
-	-	On Request	On Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.	845614-11-1
Product Name	Bitopertin

Biological Targets

SLC6A9

Associated Conditions

obsessive-compulsive disorder·schizophrenia·Diamond-Blackfan anemia·Beta-thalassemia·erythropoietic protoporphyria

* The information provided here is compiled from public sources and is for reference only.

Bitopertin

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Bitopertin

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Documentation

Bitopertin

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.

Bitopertin

Pricing & Availability

Product Information

Biological Profile

Properties

Biological Targets

Associated Conditions

Related Articles

Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.

Documentation